Sanuwave Receives U.S. Patent for the Use of Shock Waves in Cleaning and Grooming of Water Submerged Structures

Suwanee, GA,(Uptick Newswire – February 1, 2018) – SANUWAVE Health, Inc. (OTCQB: SNWV), announced today the receipt of U.S. Pat. No. 9,840,313 from the U.S. Patent and Trademark Office entitled “Cleaning and Grooming Water Submerged Structures Using Acoustic Pressure Shock Waves” that has a patent life to September 2036.

The patent includes twenty-four claims relating to the apparatuses and methods that use shock waves for the cleaning and grooming of submerged structures, such as ships, boats, watercrafts or platform structures, to name a few.  Shock waves can be generated with laser electrohydraulic, or spark-gap electrohydraulic, or electromagnetic, or piezoelectric systems that are placed on a remotely operated underwater vehicle.  Besides shock wave devices, the system includes inspection modules, lights, cameras, and one or more fluid jet nozzles.  The cleaning of fouling or grooming of marine biofilms using shock waves is done without imparting material stress, paint or coating damage to the underlying surface of the submerged structure.

“This new patent continues to extend the reach of our technology and our patent portfolio beyond regenerative medicine and fits with our long-term strategy to maximize the value of our shock wave technology in non-medical fields.  As the matter of fact, in the past 5 years we have added 20 additional patents and patent applications to bring the Company’s total to 68, which shows our commitment to innovation and the continuous search to find new applications for our proprietary technology,” commented Kevin A. Richardson II, the Chairman of the board of directors of SANUWAVE.

SANUWAVE’s new patent teaches a novel modality to remotely and automatically clean in a safe manner, without the need to use divers, the submerged structures in a non-contact and non-abrasive way that is potentially non-destructive to paints or coatings, including antifouling or environmental coatings applied to the water vessel or underwater structure, which is an important financial and environmental benefit.  Furthermore, the systems and methods presented into this patent can be applied for ships at dockside or out to sea or on a lake or on a river, without the need to use dry-docks for cleaning, which is not only a large expense but a risk to the structure of the vessel each time it is removed from the water.   This fits the needs of low maintenance and environmentally-friendly systems required by the ship industry and navy.

“Cleaning and grooming of the fouling and biofilms formed on water submerged structures represents a new application for shock waves, which answers an important need of the modern society and opens new opportunities for SANWUAVE’s technology to be applied successfully outside the medical arena.  Small-scale testing at Montana State University and out in the field proved that indeed our technology can successfully clean marine biofilms and fouling.  We are now ready to begin exploring strategic partnerships to bring this technology to an effective application in practice and successful commercialization.” concluded Mr. Richardson.

SANUWAVE Health Inc., and its wholly owned subsidiary SANUWAVE, Inc., now have 68 patents (issued or pending) in the field of shock waves used in medical and non-medical applications.

About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (OTCQB:SNWV) ( is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is US FDA cleared for the treatment of Diabetic Foot Ulcers.  The device is also CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, South Korea, Australia and New Zealand. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotron® and orthoPACE® devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE’s shock wave technology for non-medical uses, including energy, water, food and industrial markets.

Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.

For additional information about the Company, visit


Millennium Park Capital LLC
Christopher Wynne

SANUWAVE Health, Inc.
Kevin Richardson II, Chairman of the Board


Source: Uptick Newswire

Leave a Reply